This company has been marked as potentially delisted and may not be actively trading. Innovate Biopharmaceuticals (INNT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock INNT vs. VAXX, SCPS, EVLO, CMRA, ARDS, CALA, STAB, AMPE, EFTR, and MTEMShould you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Vaxxinity (VAXX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), and Molecular Templates (MTEM). These companies are all part of the "medical" sector. Innovate Biopharmaceuticals vs. Vaxxinity Scopus BioPharma Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Calithera Biosciences Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Molecular Templates Innovate Biopharmaceuticals (NASDAQ:INNT) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Which has stronger valuation & earnings, INNT or VAXX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnovate BiopharmaceuticalsN/AN/A-$27.05MN/AN/AVaxxinityN/AN/A-$56.93M-$0.45-0.03 Do insiders & institutionals hold more shares of INNT or VAXX? 5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor INNT or VAXX? Innovate Biopharmaceuticals received 198 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 65.48% of users gave Innovate Biopharmaceuticals an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformInnovate BiopharmaceuticalsOutperform Votes20365.48% Underperform Votes10734.52% VaxxinityOutperform Votes538.46% Underperform Votes861.54% Is INNT or VAXX more profitable? Company Net Margins Return on Equity Return on Assets Innovate BiopharmaceuticalsN/A N/A -234.42% Vaxxinity N/A N/A N/A Does the media refer more to INNT or VAXX? In the previous week, Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment Innovate Biopharmaceuticals Neutral Vaxxinity Neutral Which has more risk & volatility, INNT or VAXX? Innovate Biopharmaceuticals has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -19.23, meaning that its share price is 2,023% less volatile than the S&P 500. SummaryInnovate Biopharmaceuticals and Vaxxinity tied by winning 4 of the 8 factors compared between the two stocks. Get Innovate Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INNT vs. The Competition Export to ExcelMetricInnovate BiopharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8,000.00$6.63B$5.42B$7.75BDividend YieldN/A3.20%5.44%4.31%P/E Ratio-1.797.1322.2118.28Price / SalesN/A238.37389.19101.44Price / CashN/A65.6738.2034.62Price / BookN/A6.256.644.16Net Income-$27.05M$142.48M$3.21B$247.58M Innovate Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A$8,000.00N/A-1.798Gap DownVAXXVaxxinityN/A$0.00-98.0%N/A-88.3%$25,000.00N/A0.0090Gap UpSCPSScopus BioPharmaN/A$0.00flatN/A-81.3%$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030CALACalithera BiosciencesN/A$0.00flatN/A-82.8%$5,000.00N/A0.0060Analyst ForecastSTABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00+250.0%N/A-99.3%$2,000.00N/A0.0020Analyst ForecastEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010MTEMMolecular TemplatesN/A$0.00-50.0%N/AN/A$1,000.00$23.48M0.00260Gap Down Related Companies and Tools Related Companies VAXX Competitors SCPS Competitors EVLO Competitors CMRA Competitors ARDS Competitors CALA Competitors STAB Competitors AMPE Competitors EFTR Competitors MTEM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INNT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INNT Stock Free INNT Stock Alerts